AstraZeneca, which has partnered with the University of Oxford in the vaccine race has successfully entered phase III critical trials in the US. The Oxford vaccine was one of the first ones to have entered into human clinical trials and announced the start of phase III. The news of the start of US leg of the trials was announced by Donald Trump himself, recently.
British-Swedish pharmaceutical giant, AstraZeneca has also entered into a strategic partnership with global firms. According to a briefing, the company is looking to enrol up to 30,000 adults across 80 sites in the US.
“Trial centres across the US are recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus,”